Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
NCT ID: NCT01732926
Last Updated: 2018-11-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
475 participants
INTERVENTIONAL
2013-01-02
2016-05-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
NCT01732913
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
NCT01569295
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
NCT02044822
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
NCT01059630
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
NCT02258529
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rituximab + Bendamustine + Idelalisib
Participants will receive rituximab + bendamustine + idelalisib.
Idelalisib
150 mg tablet administered orally twice daily
Rituximab
375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
Bendamustine
90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
Rituximab + Bendamustine + Placebo
Participants will receive rituximab + bendamustine + placebo.
Rituximab
375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
Bendamustine
90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
Placebo
Tablet administered orally twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Idelalisib
150 mg tablet administered orally twice daily
Rituximab
375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
Bendamustine
90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
Placebo
Tablet administered orally twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Follicular lymphoma (FL) Grade 1, 2, or 3a
2. Small lymphocytic lymphoma (SLL)
3. Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
4. Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)
* Ongoing drug-induced liver injury, active hepatitis C, active hepatitis B, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
* Prior treatment with bendamustine that was not effective.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clearview Cancer Institute
Huntsville, Alabama, United States
Ironwood Cancer and Research Center
Chandler, Arizona, United States
Comprehensive Blood and Cancer Center (Bakersfield)
Bakersfield, California, United States
Saint Jude Heritage Healthcare (TORI)
Fullerton, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
Cancer Care Associates
Redondo Beach, California, United States
San Luis Obispo Oncology and Hematology
San Luis Obispo, California, United States
Cancer Center of Santa Barbara
Santa Barbara, California, United States
Central Coast Medical Oncology Group
Santa Maria, California, United States
St Joseph Heritage Healthcare System
Santa Rosa, California, United States
Kaiser Permanente Vallejo Medical Center
Vallejo, California, United States
Sylvester Comprehensive Cancer Center/UMHC
Deerfield Beach, Florida, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
Northwest Georgia Oncology Centers, PC
Marietta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
Joliet Oncology Hematology Associates Ltd.
Joliet, Illinois, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
North Shore Hematology/Oncology Associates
East Setauket, New York, United States
Weill Cornell Medical College
New York, New York, United States
Signal Point Clinical Research Center, LLC
Middletown, Ohio, United States
Hollings Cancer Center
Charleston, South Carolina, United States
Bon Secours Saint Francis Hospital
Greenville, South Carolina, United States
Texas Oncology, P.A.
Bedford, Texas, United States
Charles A. Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology, P.A.
Denton, Texas, United States
Brooke Army Medical Center
Fort Sam Houston, Texas, United States
Texas Oncology, P.A.
Harlingen, Texas, United States
Texas Oncology, P.A.
Weslaco, Texas, United States
Swedish Medical Center
Seattle, Washington, United States
Northwest Medical Specialists
Tacoma, Washington, United States
Aurora BayCare Medical Center
Green Bay, Wisconsin, United States
Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Prince of Wales Hospital
Randwick, New South Wales, Australia
Haematology and Oncology Clinics of Australia Gold Coast
South Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Adelaide Cancer Centre
Kurralta Park, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Saint Vincent's Hospital
Fitzroy, Victoria, Australia
Western Hospital
Footscray, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Tom Baker Cancer Center
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Fraser Clinical Trials, Inc.
New Westminster, British Columbia, Canada
BC Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada
Queen Elizabeth II Health Sciences Centre, Centre for Clinical Research
Halifax, Nova Scotia, Canada
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Hôpital Charles Lemoyne
Greenfield Park, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Centre Hospitalier Affilie Universitaire de Quebec
Québec, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
CancerCare Manitoba
Winnipeg, , Canada
Fakultní Nemocnice Ostrava
Ostrava - Poruba, Severomoravsky KRAJ, Czechia
Fakultní nemocnice Brno
Brno, , Czechia
Fakultní nemocnice Hradec Králové
Hradec Králové, , Czechia
CHR Metz
Metz, Alsace, France
Centre Hospitalier Universitaire de Strasbourg - Hôpital Hautepierre
Strasbourg, Alsace, France
Institut Bergonié
Bordeaux, Aquitaine, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Centre Henri-Becquerel
Rouen, Haute-normandie, France
Centre Jean Bernard
Le Mans, Pays de la Loire Region, France
Centre Hospitalier Universitaire Brest
Brest, , France
Centre Hospitalier de Dunkerque
Dunkirk, , France
Centre Hospitalier Départmental La Roche sur Yon
La Roche-sur-Yon, , France
Centre Léon Bérard
Lyon, , France
Institut Paoli Calmettes
Marseille, , France
Hôpital Hôtel-Dieu
Nantes, , France
Centre Hospitalier Universitaire de Poitiers
Poitiers, , France
Centre Hospitalier Régional et Universitaire - Hôpital Bretonneau
Tours, , France
Institut Gustave Roussy
Villejuif, , France
Hôpital Necker-Enfants Malades
Paris, Île-de-France Region, France
Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Villingen-Schwenningen, Baden-Wurttemberg, Germany
Gemeinschaftspraxis Dres. Söling Und Siehl
Kassel, Hesse, Germany
Vivantes Klinikum am Urban
Berlin, , Germany
Charite - Campus Virchow
Berlin, , Germany
Klinikum der Ludwig-Maximilians-Universität München
München, , Germany
Barzilai Medical Center
Ashkelon, , Israel
Soroka University Medical Center
Beersheba, , Israel
Rambam Health Corp.
Haifa, , Israel
Hadassah Medical Organization, Ein Kerem
Jerusalem, , Israel
Centro di Riferimento Oncologico di Aviano
Aviano, , Italy
Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
Bologna, , Italy
Spedali Civili Di Brescia Azienda Ospedaliera
Brescia, , Italy
IRCCS Azienda Ospedaliera Universitaria San Martino
Genova, , Italy
Ospedale San Raffaele-IRCCS
Milan, , Italy
Azienda Ospedaliera Ospedale Niguarda Ca' Granda
Milan, , Italy
Azienda Ospedaliero Universitaria (AOU) "Maggiore della Carita" di Novara
Novara, , Italy
Azienda Ospedaliera Ospedali Riuniti Marche Nord
Pesaro, , Italy
Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto
Piacenza, , Italy
Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte
Siena, , Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Torino, , Italy
Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
Malopolskie Centrum Medyczne S.C.
Krakow, , Poland
Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi
Lódz, , Poland
Szpital Kliniczny nr 1, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku
Lublin, , Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim
Olsztyn, , Poland
Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku
Słupsk, , Poland
Centralny Szpital Kliniczny MSW w Warszawie
Warsaw, , Poland
Instytut Hematologii i Transfuzjologii
Warsaw, , Poland
Centrum Onkologii i Hipertermii
Warsaw, , Poland
N. N. Blokhin Russian Cancer Research Center
Moscow, , Russia
Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko
Nizhny Novgorod, , Russia
Ryazan Regional Clinical Hospital
Ryazan, , Russia
FGU Russian Scientific Research Institute of Hematology and Transfusiology
Saint Petersburg, , Russia
Saint Petersburg I.P. Pavlov State Medical University
Saint Petersburg, , Russia
FSI "V.A. Almazov Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies"
Saint Petersburg, , Russia
Saratov State Medical University
Saratov, , Russia
State Budgetary Healthcare Institution "Volgograd Regional Clinical Oncology Dispensary #1"
Volgograd, , Russia
Sverdlovsk Regional Clinical Hospital #1
Yekaterinburg, , Russia
Central City Hospital # 7
Yekaterinburg, , Russia
Dong-A University Medical Center
Busan, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain
Hospital Universitari Germans Trias i Pujol
Badalona, , Spain
Hospital Universitario La Princesa
Madrid, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Hospital Clínico Universitario de Salamanca
Salamanca, , Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Universitari i Politecnic La Fé de Valencia
Valencia, , Spain
Karolinska Universitetssjukhuset
Huddinge, Stockholm County, Sweden
Länssjukhuset Ryhov
Jönköping, , Sweden
Changhua Christian Hospital
Changhua, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
National Cheng-Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Kent and Canterbury Hospital
Canterbury, England, United Kingdom
University Hospital Coventry
Coventry, England, United Kingdom
Royal Bournemouth General Hospital
Dorset, England, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
Barts and The London NHS Trust
London, England, United Kingdom
University College London Hospitals National Health Society Foundation Trust
London, England, United Kingdom
Guys and Saint Thomas NHS Foundation Trust
London, England, United Kingdom
Imperial College Healthcare NHS Trust
London, England, United Kingdom
Maidstone Hospital
Maidstone, England, United Kingdom
Christie Hospital NHS Foundation Trust
Manchester, England, United Kingdom
Oxford University Hospitals NHS Trust
Oxford, England, United Kingdom
Southampton General Hospital
Southampton, England, United Kingdom
Mount Vernon Hospital
Middlesex, , United Kingdom
New Cross Hospital
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-004034-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GS-US-313-0125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.